In an amendment to its S-1 filing with the SEC, Elixir Pharmaceuticals revealed that it hopes to sell 5,750,000 shares at $16 or $92,000,000, an increase of $1 per share over an earlier filing. Apparently, ELXR and its underwriters hope to ride the wave of excitement generated by both Sirtris and other companies that presented at the JP Morgan Health Care conference.
ELXR S-1A Filing
The Sirtuin Investor speculates that the current equity market anxiety will make a successful IPO difficult. If the IPO is successful, Elixir will become the third public company that has announced a formal research program that focuses on sirtuins in the development of new drugs, Pharmion and Sirtris are the others.
Due your own due dilligence and remember....immortality is expensive
Tuesday, January 8, 2008
Subscribe to:
Post Comments (Atom)
2 comments:
ELXR is not really persuing SIRT1 drugs like Sirtris. It seams they have given up on SIRT activators. Sirtris is too far ahead. That expains why Lenny left.
"That focus has been notably waning at Elixir, which hopes to raise $86 million in its own upcoming IPO. Elixir asserts in its IPO registration statement that its researchers “mine the pathways involved in the regulation of aging discovered by our founders”—but the company’s main commercial hopes rest on Glinsuna and Metgluna, diabetes drugs that it has licensed from a Japanese manufacturer and aims to market in the United States, pending FDA approval. In its 179-page IPO registration statement filed with the SEC, the company does not detail its research on drugs aimed at affecting the activity of sirtuins until page 69—and then, it’s in reference to drugs that block Sir2, rather than enhancing it. (The company believes that blocking sirtuins may help in the treatment of cancer.)"
http://www.xconomy.com/2007/11/19/sir2-roads-diverged-elixir-co-founder-joins-rival-sirtris/
Larry,
You are absolutely correct. Eilixr's main goal seems to be commericializing existing drugs. Based upon the S-1, sirtuin work is an afterthought. However, I was simply trying to point out how little work is being done on sirtuins in the industry beyond the work at Sirtis.
Post a Comment